Six-Month Deep Vein Thrombosis Outcomes by Chronicity: Analysis of the Real-World ClotTriever Outcomes Registry. 

 -  2023 
<br/><br/>Available online through MWHC library: 2002 - 2006, Available in print through MWHC library: 1999 - 2006 
<br/><br/> CONCLUSIONS: Mechanical thrombectomy using the ClotTriever System with adjunctive venoplasty and stent placement is safe and similarly effective for acute, subacute, and chronic DVT. Copyright © 2023 SIR. Published by Elsevier Inc. All rights reserved.  MATERIALS AND METHODS: Real-world patients with lower extremity DVT were treated with the ClotTriever System (Inari Medical, Irvine, California). Adjuvant venoplasty, stent placement, or both were performed at the physician's discretion. Thrombus chronicity was determined by visual inspection of removed thrombus, categorizing patients into acute, subacute, and chronic subgroups. Serious adverse events (SAEs) were assessed through 30 days. Clinical and quality-of-life (QoL) outcomes are reported through 6 months.  PURPOSE: To analyze the first 250 patients from the prospective, multicenter, industry-sponsored ClotTriever Outcomes (CLOUT) registry, assessing the safety and effectiveness of mechanical thrombectomy for acute, subacute, and chronic deep vein thrombosis (DVT).  RESULTS: Thrombus chronicity was designated for 244 of the 250 patients (acute, 32.8%; subacute, 34.8%; chronic, 32.4%) encompassing 254 treated limbs. Complete or near-complete (>=75%) thrombus removal was achieved in 90.8%, 81.9%, and 83.8% of the limbs with acute, subacute, and chronic thrombus, respectively. No fibrinolytics were administered, and 243 (99.6%) procedures were single sessions. One (0.4%) patient in the subacute group experienced a device-related SAE, a fatal pulmonary embolism. On comparing baseline and 6-month data, improvements were demonstrated in median Villalta scores (acute, from 10 to 1; subacute, from 9 to 1; chronic, from 10 to 3; for all, P < .0001) and mean EuroQol group 5-dimension (EQ-5D) self-report questionnaire scores (acute, 0.58 to 0.89; subacute, 0.65 to 0.87; chronic, 0.58 to 0.88; for all, P < .0001). There were no significant differences in outcomes across the subgroups. 
<br/><br/><br/>English 
<br/><br/><label>ISSN: </label>1051-0443 
<br/><br/><label>Standard No.: </label>10.1016/j.jvir.2022.12.480 [doi] S1051-0443(23)00004-0 [pii] 
<br/><br/><label>Subjects--Topical Terms: </label><br/>*Thrombectomy<br/>*Venous Thrombosis<br/>Humans<br/>Iliac Vein<br/>Prospective Studies<br/>Quality of Life<br/>Registries<br/>Retrospective Studies<br/>Thrombectomy/ae [Adverse Effects]<br/>Thrombolytic Therapy<br/>Treatment Outcome<br/>Venous Thrombosis/dg [Diagnostic Imaging]<br/>Venous Thrombosis/et [Etiology]<br/>Venous Thrombosis/th [Therapy]--Automated
<br/><br/><label>Subjects--Geographic Terms: </label><br/>MedStar Washington Hospital Center
<br/><br/><label>Index Terms--Occupation: </label><br/>Surgery/Vascular Surgery
<br/><br/><label>Index Terms--Function: </label><br/>Journal Article<br/>Multicenter Study<br/>Research Support, Non-U.S. Gov't